CAMBRIDGE, MA, USA I March 11, 2025 I Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback